BCPC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

259.59M

+8.16%

1.285

+13.72%

266.86M

+6.52%

1.310

+7.38%

269.14M

+5.35%

1.370

+7.87%

Estimates Revision

The market is revising Upward the revenue expectations for Balchem Corporation (BCPC) for FY2025, with the revenue forecasts being adjusted by 0.8% over the past three months. During the same period, the stock price has changed by 14.23%.

Revenue Estimates for FY2025

Revise Upward

+0.8%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.2%

In Past 3 Month

Stock Price

Go Up

+14.23%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast BCPC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is 176.00 USD with a low forecast of 162.00 USD and a high forecast of 190.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

162.00

Averages

176.00

High

190.00

Current: 0.000

Low

162.00

Averages

176.00

High

190.00

Rothschild & Co Redburn

Neutral

initiated

$162

2025-12-05

Reason

Rothschild & Co Redburn

Price Target

$162

2025-12-05

initiated

Neutral

Reason

Rothschild & Co Redburn initiated coverage of Balchem with a Neutral rating and $162 price target. The company has a "resilient" business model built upon niche high-growth products, the analyst tells investors in a research note. However, the firm finds Balchem's valuation as "rich" at current share levels.

H.C. Wainwright

Buy

maintain

$189 -> $190

2025-10-22

Reason

H.C. Wainwright

Price Target

$189 -> $190

2025-10-22

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Balchem to $190 from $189 and keeps a Buy rating on the shares. The firm remains confident in Balchem's long-term prospects following the Q3 beat. The company's sales performance and operational efficiency are driving growth, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$180 -> $189

2025-08-04

Reason

H.C. Wainwright

Price Target

$180 -> $189

2025-08-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Balchem to $189 from $180 and keeps a Buy rating on the shares. The company reported Q2 beat and its future growth should be driven by manufacturing expansion and anti-dumping measures, the analyst tells investors in a research note. The firm believes the European Commission's provisional anti-dumping duties on imports into the European Union of choline chloride originating in the People's Republic of China should improve the sales outlook of Balchem's choline-based products in Europe.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$190

2025-02-24

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$190

2025-02-24

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Balchem Corp (BCPC.O) is 28.36, compared to its 5-year average forward P/E of 33.16. For a more detailed relative valuation and DCF analysis to assess Balchem Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

33.16

Current PE

28.36

Overvalued PE

36.48

Undervalued PE

29.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

21.03

Current EV/EBITDA

17.94

Overvalued EV/EBITDA

23.13

Undervalued EV/EBITDA

18.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.89

Current PS

4.62

Overvalued PS

5.50

Undervalued PS

4.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1060.9% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 2062.5% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1060.9% over the last month.

Sold

Bought

BCPC News & Events

Events Timeline

No data

News

1.0

01-02Globenewswire

Balchem Corporation to Attend CJS Securities Virtual Conference with CEO and CFO on January 14, 2026

8.0

2025-12-10Globenewswire

Balchem Declares $0.96 Dividend Per Share, 10.3% Increase

1.0

2025-10-30Newsfilter

Balchem Corporation to Participate in Baird's 55th Annual Global Industrial Conference on November 12, 2025

People Also Watch

Frequently Asked Questions

What is Balchem Corp (BCPC) stock price today?

The current price of BCPC is 160.27 USD — it has decreased -0.21 % in the last trading day.

What is Balchem Corp (BCPC)'s business?

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

What is the price predicton of BCPC Stock?

What is Balchem Corp (BCPC)'s revenue for the last quarter?

Balchem Corp revenue for the last quarter amounts to 267.56M USD, increased 11.51 % YoY.

What is Balchem Corp (BCPC)'s earnings per share (EPS) for the last quarter?

Balchem Corp. EPS for the last quarter amounts to 1.24 USD, increased 20.39 % YoY.

What changes have occurred in the market's expectations for Balchem Corp (BCPC)'s fundamentals?

How many employees does Balchem Corp (BCPC). have?

Balchem Corp (BCPC) has 1361 emplpoyees as of January 10 2026.

What is Balchem Corp (BCPC) market cap?

Today BCPC has the market capitalization of 5.19B USD.